Zusammenfassung
Aktuelle Daten des Gesundheitsberichtes für Deutschland weisen Folgeerkrankungen der Atherosklerose wie z. B. Herzinfarkt und Schlaganfall als die führenden Todesursachen in Deutschland aus. In Anbetracht der alternden Gesellschaft wird das Potenzial präventivmedizinischer Maßnahmen unmittelbar sichtbar. Um dieses Potenzial auszuschöpfen und die limitierten Ressourcen mit maximaler Effizienz einzusetzen, ist es notwendig, die Risikofaktoren für kardiovaskuläre Erkrankungen hierarchisch und in ihrer Interaktion zu verstehen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ariyo AA, Haan M, Tangen CM et al. (2000) Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 102: 1773–1779
Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105: 310–315
Backer G de, Ambrosioni E, Borch-Johnsen K et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601–1610
Blair SN, Jackson AS (2001) Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc 33: 762–764
hiasson JL, Josse RG, Gomis R and the STOP-NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486–494
Dahlof B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003
Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 68: 899–917
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486–2497
Gerstein HC (2002) Dysglycemia: a key cardiovascular risk factor. Semin Vasc Med 2: 165–174
Gould AL, Rossouw JE, Santanello NC et al. (1998) Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97: 946–952
European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011–1053
Hauner H, Hamann A, Husemann B et al. (2002) Evidenzbasierte Leitlinie – Adipositas. Prävention und Therapie der Adipositas. www.adipositas-gesellschaft.de/Leitlinien/Evidenzbasierte-Leitlinien-Adipositas.pdf. Gesehen 27 Jan 2008
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22
Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3: 213–219
Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015– 2022
Humphrey LL, Chan BK, Sox HC (2002) Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137: 273–284
Klingbeil AU, Schneider M, Martus P et al. (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41–46
Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423–1430
Lewington S, Clarke R, Qizilbash N et al. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913
Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G (2009) Homocysteine-Lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009; Oct 7(4): CD006612. DOI: 10.1002/14651858. CD006612.pub2
Peters AL, Davidson MB, Schriger DL, Hasselblad VA (1996) A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 276: 1246–1252
Ridker PM, Rifai N, Rose L, et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565
Ridker PM, Danielson E, Fonseca FAH et al. (2009) Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 359: 2195–2207
Rifai N, Buring JE, Lee IM et al. (2002) Is C-reactive protein specific for vascular disease in women? Ann Intern Med 136: 529–533
Rosengren A, Hawken S, Ounpuu S et al. (2004) Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study). Lancet 364: 953–962
Rucker D, Padwal R, Li SK et al (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194–1199
Schramm TK, Gislason GH, Køber L et al. (2008) Diabetes patients requiring glucose-lowering therapy and non-diabetics with a prior myocardial infarction carry the same cardiovascular risk. Circulation 117: 1945– 1954
Silagy C, Lancaster T, Stead L et al. (2002) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 4:CD000146
Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823–2828
Thompson PD, Buchner D, Pina IL et al. (2003) Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107: 3109–3116
Tzoulaki I, Molokhia M, Curcin V et al. (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs:retrospective cohort study using UK general practice research database. Br Med J 339: b4731. DOI: 10.1136/ bmj.b4731
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schneider, C. (2011). Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. In: Erdmann, E. (eds) Klinische Kardiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16481-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-16481-1_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-16480-4
Online ISBN: 978-3-642-16481-1
eBook Packages: Medicine (German Language)